Fawzi Benzaghou

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Robin Kate Kelley, Lorenza Rimassa, Ann‐Lii Cheng et al. · The Lancet Oncology · 2022 · 522 citations · Full text

Medicine, Oncology, Pharmacology +17

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

Zev A. Wainberg, Davide Melisi, Teresa Macarulla et al. · The Lancet · 2023 · 439 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial

Abdel-Rahmène Azzouzi, S. Vincendeau, Éric Barret et al. · The Lancet Oncology · 2016 · 330 citations

Medicine, Oncology, Pharmacology +15

Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure

Abdel-Rahmène Azzouzi, Souhil Lebdai, Fawzi Benzaghou et al. · World Journal of Urology · 2015 · 90 citations · Full text

Medicine, Oncology, Pharmacology +16

VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial

Robin Kate Kelley, Thomas Yau, Ann‐Lii Cheng et al. · Annals of Oncology · 2021 · 84 citations · Full text

Medicine, Oncology, Pharmacology +14